FIELD: biotechnologies.
SUBSTANCE: physiologically active protein or polypeptide are fused with version of alpha-1-antitrypsin, which has at least one mutated aminoacid residue. Mutations are performed in the following positions: asparagine residue instead of proline residue in position 357; or asparagine residue instead of proline residue in position 357 and threonine residue instead of serine in position 359; or asparagine residue instead of proline residue in position 357 and serine residue instead of cysteine in position 232; or asparagine residue instead of proline residue in position 357, threonine residue instead of serine in position 359 and serine residue instead of cysteine in position 232.
EFFECT: invention allows increasing half lifetime of physiologically active protein or polypeptide in vivo by maintaining its stable circulation in blood.
7 cl, 13 dwg, 7 ex
Title | Year | Author | Number |
---|---|---|---|
NEW VERSION OF ALPHA-1-ANTITRYPSIN, METHOD OF ITS PRODUCTION AND APPLICATION | 2012 |
|
RU2567007C1 |
Fc-FRAGMENT IgG4 CONTAINING MODIFIED HINGE REGION | 2014 |
|
RU2696973C2 |
PROTEIN COMPLEX, OBTAINED BY USING FRAGMENT OF IMMUNOGLOBULIN, AND METHOD OF SUCH COMPLEX OBTAINING | 2004 |
|
RU2356909C2 |
IGG4 Fc FRAGMENT CONTAINING A MODIFIED HINGE REGION | 2014 |
|
RU2800558C1 |
POLYPEPTIDE COMPLEX CONTAINING NON-PEPTIDYL POLYMER, HAVING THREE FUNCTIONAL ENDS | 2009 |
|
RU2483081C2 |
HYBRID STRUCTURE, INCLUDING ANTIGEN-BINDING FRAGMENT SPECIFIC TO SERUM ALBUMIN AND EFFECTOR COMPONENT AND METHODS FOR PREPARATION THEREOF | 2014 |
|
RU2661087C2 |
PHARMACEUTICAL COMPOSITION CONTAINING Fc-REGION OF IMMUNOGLOBULIN AS CARRIER | 2004 |
|
RU2352583C2 |
FUSED IMMUNOGLOBULIN PROTEINS | 2008 |
|
RU2530168C2 |
PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE SHOWING PROLONGED HALF-TIME INDEX IN VIVO | 2004 |
|
RU2312868C2 |
MODIFIED COAGULATION FACTOR VIIa WITH EXTENDED HALF-LIFE | 2007 |
|
RU2466141C2 |
Authors
Dates
2014-01-10—Published
2010-04-22—Filed